A

Axsome Therapeutics

D
AXSM
USD
2.77
(3.0257%)
Market Closed
10,579.00
Volume
-5.62
EPS
-
Div Yield
-14.334347
P/E
4,527,379,335.60
Market Cap
Today
3.0257%
1 Week
2.790%
1 Month
4.487%
6 Months
22.701%
12 Months
29.152%
Year To Date
18.478%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ACAD
0.11
(0.6736%)
USD
A
ADMP
(%)
USD
A
ANVS
0.31
(3.6993%)
USD
A
ARDX
0.085
(1.4382%)
USD
A
AXDX
-0.02
(-1.3423%)
USD
B
BIIB
3.82
(1.9334%)
USD
B
BNR
0.12
(3.6145%)
USD
C
CAH
-0.66
(-0.5925%)
USD
C
CFRX
(%)
USD
E
EGRX
-0.04
(-0.9195%)
USD
I
IONS
0.38
(0.8971%)
USD
MRK
MRK
-1.44
(-1.2137%)
USD
NVS
NVS
-0.02
(-0.0172%)
USD
PFE
PFE
-0.09
(-0.3025%)
USD
Q
QURE
-0.1
(-1.7391%)
USD
S
SGMO
0.0617
(7.3584%)
USD
T
TNXP
0.0048
(3.3081%)
USD
VRTX
VRTX
3.93
(0.8292%)
USD

Title:
Axsome Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Do you need help or have a question?
Contact Us